Aquestive Therapeutics Securities Fraud Lawsuits
Analysis based on 60 articles · First reported Apr 01, 2026 · Last updated Apr 27, 2026
The class action lawsuits against Aquestive Therapeutics by Rosen Law Firm and Pomerantz LLP have negatively impacted the company's stock price, which fell by 37.04% after the United States — Food and Drug Administration identified deficiencies in its Anaphylm NDA. This event highlights the risks associated with pharmaceutical companies' drug approval processes and the potential for significant financial losses for investors due to alleged misleading statements.
Aquestive Therapeutics is facing multiple class action lawsuits filed by Rosen Law Firm and Pomerantz LLP. The lawsuits allege that Aquestive Therapeutics made false and misleading statements and failed to disclose the true state of its New Drug Application (NDA) for Anaphylm. Specifically, the company is accused of concealing or minimizing the significance of human factors involved in the use and deployment of its sublingual film, including packaging, administration, and labeling. The United States — Food and Drug Administration identified deficiencies in the Anaphylm NDA, which effectively delayed its approval indefinitely. This news led to a significant drop in Aquestive Therapeutics' stock price, causing damages to investors who purchased securities between June 16, 2025, and January 8, 2026. Both law firms are encouraging affected investors to join the class action and seek lead plaintiff status by the May 4, 2026, deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard